Fact-checked by Grok 2 weeks ago

GDF15

Growth Differentiation Factor 15 (GDF15), also known as macrophage inhibitory cytokine-1 (MIC-1) or nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1), is a stress-responsive cytokine and a divergent member of the transforming growth factor beta (TGF-β) superfamily. Encoded by the GDF15 gene located on chromosome 19p13.11, it is synthesized as a 308-amino-acid precursor protein that undergoes proteolytic cleavage by proprotein convertases to form a mature 25 kDa disulfide-linked homodimer. First identified in 1997 through cloning strategies in activated macrophages, GDF15 circulates in the bloodstream and plays a central role in cellular stress responses, including inflammation, tissue injury, and metabolic regulation. GDF15 exerts its effects primarily by binding to the glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) in the , particularly in the and nucleus tractus solitarius, often in association with the RET coreceptor to activate downstream signaling pathways such as ERK1/2, AKT, and Smad2/3. This interaction suppresses appetite, promotes , and enhances energy expenditure, contributing to its role in maintaining metabolic . Beyond metabolism, GDF15 modulates inflammatory processes and acts as a survival factor in response to cellular stressors like , oxidative damage, and stress. Elevated circulating levels of GDF15 are observed in various pathological conditions, serving as a biomarker for cellular aging, systemic inflammation, and diseases including obesity, type 2 diabetes, cardiovascular disorders, cancer, and neurodegenerative processes. In cancer, it exhibits dual roles, potentially inhibiting tumor growth in some contexts while promoting progression and cachexia in others. Due to its potent effects on appetite suppression and insulin sensitivity, GDF15 and its receptor agonists are being investigated as therapeutic targets for obesity and related metabolic syndromes, with preclinical studies demonstrating significant weight reduction in animal models; as of 2025, early clinical trials (e.g., Phase 2 for MBL949) have progressed but shown variable efficacy in inducing weight loss in humans.

Discovery and molecular biology

Discovery and nomenclature

Growth/differentiation factor 15 (GDF15) was initially discovered in 1997 through independent efforts by multiple research groups, who identified it as a novel protein with growth and differentiation factor activity, particularly prominent in placental tissue. Hromas et al. cloned the gene from a human placental cDNA library and named it PLAB (placental bone morphogenetic protein), noting its high expression in and potential role in bone morphogenetic processes as a divergent member of the TGF-β superfamily. Concurrently, Bootcov et al. identified the same protein from lipopolysaccharide-activated monocyte-derived s using subtractive hybridization, designating it MIC-1 (macrophage inhibitory cytokine-1) due to its ability to inhibit macrophage activation and its structural similarity to TGF-β cytokines. Subsequent studies in 1998 further characterized the protein and introduced additional names based on tissue-specific expression and functional contexts. Paralkar et al. cloned the cDNA from both placental and libraries, naming it PTGFB (placental transforming growth factor-β) for its placental abundance and TGF-β-like features, while also referring to it as PDF (prostate factor) owing to its expression in prostate tissue and potential involvement in . Later, in 2001, Baek et al. identified the gene as NAG-1 (non-steroidal anti-inflammatory drug-activated gene) after observing its upregulation in cells treated with NSAIDs like , highlighting its proapoptotic and antitumorigenic properties independent of inhibition. The nomenclature evolved to GDF15 to reflect its classification within the TGF-β superfamily, with the official designation solidified in comparative genomic analyses. Böttner et al. (1999) characterized the , , and orthologs, confirming and naming it GDF-15/MIC-1 to unify prior aliases under the growth/differentiation factor framework, emphasizing its distant relation to other TGF-β family members like BMPs and GDFs. This standardization facilitated subsequent research into its roles across species and tissues.

Gene and protein structure

The GDF15 gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.11, spanning approximately 14.4 kb from genomic positions 18,374,731 to 18,389,176 (GRCh38 assembly). The gene consists of two s, with the first exon encoding the 5' untranslated region and the signal peptide, and the second exon containing the coding sequence for the prodomain and mature protein. This , including conserved synteny with flanking genes such as PGPEP1 and LRRC25, is maintained across mammalian species, reflecting evolutionary stability in the region. The GDF15 gene encodes a 308-amino acid preproprotein, which includes a 29-residue N-terminal , a 167-residue prodomain, and a 112-residue C-terminal domain that forms the bioactive moiety. Upon processing, the GDF15 protein assembles into a disulfide-linked homodimer with an apparent molecular weight of 25 kDa under non-reducing conditions. Central to its maturation is a conserved RXXR furin-like cleavage site (Arg193-Ser-Ser-Arg196) that facilitates intracellular proteolytic release of the domain from the propeptide. The domain features seven conserved residues that form an intermolecular and an intramolecular , stabilizing the dimeric and conferring a TGF-β superfamily-like β-sheet-rich fold essential for ligand-receptor interactions. Post-translational modifications on the prepro-GDF15 include N-linked glycosylation at Asn70 in the prodomain, which influences and stability, as well as at Ser44, contributing to proper folding and processing. These modifications occur primarily in the and Golgi apparatus, ensuring the protein's correct trafficking and bioactivity prior to as a latent complex of the mature dimer non-covalently associated with the prodomain.

Expression and signaling

Expression patterns

GDF15 exhibits low-level basal expression in several tissues, including the placenta, prostate, and kidney, where it is detectable in placental trophoblasts, prostate epithelium, and renal cells. In contrast, expression is inducible and markedly upregulated in the liver, heart, lung, and macrophages in response to cellular stress conditions such as inflammation, injury, or oxidative damage. During development, GDF15 expression in the peaks in the third , around gestational weeks 33–35, supporting function and placental maturation. Postnatally, circulating and levels of GDF15 decline rapidly. In preterm infants, they reach values by approximately 36 weeks postmenstrual age. In term infants, levels decrease significantly within the first week of life. Recent studies have shown GDF15 expression is nearly absent in pre-adipocytes but strongly upregulated during . Expression of GDF15 is upregulated by environmental stressors, including through stabilization of HIF-1α, via activation of NRF2 pathways, and DNA damage leading to activation, which binds directly to the GDF15 promoter. Specific pharmacological inducers include non-steroidal drugs (NSAIDs) such as , which potently stimulate hepatic and colonic GDF15 production, and metformin, which elevates GDF15 levels via AMPK-mediated integrated stress responses to promote metabolic adaptations.

Signaling pathways

GDF15, a member of the transforming growth factor-β (TGF-β) superfamily, exerts its biological effects primarily through binding to the GDNF family receptor alpha-like (GFRAL), a co-receptor that associates with the RET proto-oncogene receptor to form a signaling complex. The mature GDF15 protein exists as a -linked homodimer, stabilized by an interchain disulfide bond that is essential for its structural integrity and receptor-binding affinity. Upon binding, the GDF15 dimer engages two GFRAL molecules, recruiting two RET receptors to form a heterotetrameric complex, which leads to RET autophosphorylation and activation of downstream intracellular signaling cascades. In addition to this primary pathway, GDF15 exhibits weak interactions with TGF-β receptors TGFBR1 and TGFBR2, though these are not the dominant mechanism for its signaling. The activated GFRAL-RET complex primarily transduces signals through RET-mediated , initiating multiple kinase pathways including the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway and the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway. These pathways regulate cellular processes such as proliferation, survival, and metabolism, with MAPK/ERK activation promoting transcriptional responses via of ERK1/2, and PI3K/AKT enhancing cell survival through AKT . In the , GDF15 signaling via GFRAL-expressing neurons in the and nucleus of the solitary tract suppresses by modulating neural circuits that control feeding behavior, independent of canonical or pathways. Additionally, as of 2025, GDF15 has been implicated in regulating development and growth of sympathetic neurons through GFRAL signaling. GDF15 also mediates effects through SMAD-independent routes, distinct from the canonical TGF-β/SMAD signaling observed in other family members. These effects involve non-canonical pathways such as MAPK/ERK and PI3K/AKT, which dampen pro-inflammatory production and modulate immune cell activity without relying on SMAD2/3 . For instance, in cardiac tissue, GDF15 protects against via both SMAD-dependent and SMAD-independent mechanisms, including MAPK/ERK and PI3K/AKT pathways.

Physiological roles

Normal cellular functions

GDF15 plays a key role in promoting cell survival and protection from within healthy cellular environments, particularly through p53-dependent pathways that mitigate damage to preserve tissue . As a direct transcriptional target of the tumor suppressor , GDF15 is induced in response to cellular signals that activate , leading to cytoprotection in cells experiencing genotoxic stress or developmental cues. This mechanism is evident in various cell types, including epithelial cells, where GDF15 expression supports survival and reduces , thereby preventing the accumulation of damaged cells. In normal tissues, such as the , GDF15 contributes to organ development. Beyond regulation, GDF15 exerts effects that maintain immune by modulating activity and secretion. Specifically, GDF15 inhibits the activation of macrophages toward a pro-inflammatory , instead favoring an M2-like state that limits excessive immune responses in steady-state conditions. This suppression extends to key cytokines, where GDF15 reduces the production of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by interfering with signaling pathways in macrophages, thereby preventing unwarranted that could disrupt normal function. Experimental evidence from macrophage cultures demonstrates that recombinant GDF15 treatment significantly attenuates TNF-α and IL-6 release in response to standard inflammatory stimuli, underscoring its role in fine-tuning innate immune responses during routine physiological processes like surveillance. In the context of vascular maintenance and repair, GDF15 supports by inducing (VEGF) expression in endothelial cells, which is crucial for physiological vessel formation and tissue regeneration. This induction occurs through modulation of the /HIF-1α axis, where GDF15 upregulates VEGF transcription, enhancing endothelial proliferation, migration, and tube formation to facilitate nutrient delivery in developing or remodeling tissues. During , GDF15 promotes epithelial repair and vascularization at injury sites, as evidenced by delayed healing in GDF15-deficient models, where reduced VEGF-driven impairs functional vessel restoration. These actions highlight GDF15's contribution to coordinated tissue repair mechanisms, often mediated via TGF-β receptor signaling, independent of specialized receptors like GFRAL/RET.

Role in stress and homeostasis

GDF15 plays a crucial role in the body's adaptive response to physiological , acting as a stress-responsive that helps maintain by mitigating cellular damage and regulating systemic processes. Expressed inducibly under conditions such as , GDF15 promotes cytoprotection and metabolic adjustments to preserve organ function and energy balance during acute challenges. In organ injury, particularly ischemia-reperfusion scenarios, GDF15 exhibits cytoprotective effects on key cell types. In the heart, GDF15 protects cardiomyocytes from and following ischemia-reperfusion injury, reducing infarct size and preserving cardiac function through activation of (PI3K) and Akt signaling pathways. Similarly, in the liver, GDF15 safeguards hepatocytes against ischemia-reperfusion damage by enhancing oxidation, suppressing , and alleviating , thereby limiting tissue injury and supporting recovery. These actions underscore GDF15's function as an endogenous defender against reperfusion-induced and cell death in vital organs. GDF15 also contributes to metabolic under stress by modulating and energy utilization via its receptor GFRAL in the . Binding to GFRAL, GDF15 suppresses food intake and promotes energy expenditure, facilitating and improved glycemic control in response to nutritional or metabolic challenges, such as high-fat diets. This signaling pathway enhances , oxidative , and , helping to restore energy balance and prevent excessive fat accumulation during periods of caloric surplus or stress. During , GDF15 supports maternal adaptation in early by regulating through elevations in circulating levels, primarily of fetal origin. Produced mainly by the , GDF15 acts on maternal GFRAL neurons to induce aversion to potentially harmful foods and contribute to and , thereby protecting fetal development while promoting nutritional adjustments essential for . This transient increase aids in suppression and emetic responses, with symptom severity linked to GDF15 levels and maternal sensitivity, contributing to overall maternal-fetal balance without leading to pathological extremes in most cases.

Pathophysiological roles

In cardiovascular and metabolic diseases

GDF15 expression is upregulated in atherosclerotic , where it influences plaque composition and stability through modulation of and activity. Studies in animal models have shown that GDF15 deficiency reduces lesion size and enhances plaque stability by impairing migration and promoting deposition, suggesting that elevated GDF15 may contribute to plaque vulnerability in advanced . In human cohorts, circulating GDF15 levels are independently associated with the presence and extent of coronary plaques, independent of traditional cardiovascular risk factors. In , GDF15 levels are markedly elevated and correlate with disease severity, often paralleling increases in NT-proBNP, a established marker of cardiac stress. This association holds across heart failure subtypes, with higher GDF15 concentrations predicting worse functional status and hospitalization risk. Following , GDF15 exhibits protective effects by limiting infarct size and preserving cardiac function, potentially through signaling that mitigates post-injury remodeling. Its prognostic value extends to , where elevated baseline GDF15 independently forecasts and all-cause mortality, providing additive information beyond conventional risk scores. GDF15 levels rise in metabolic disorders, reflecting underlying stress responses. In obesity, circulating GDF15 is positively associated with and adiposity, yet it exerts anorexigenic effects that promote fat mass reduction and improve metabolic profiles. For , higher GDF15 concentrations correlate with elevated HbA1c, , and glycemic dysregulation, linking it to beta-cell dysfunction and disease progression. Similarly, in non-alcoholic fatty liver disease (NAFLD), GDF15 is elevated in youth and adults with or , serving as an indicator of hepatic and severity. GDF15 also mediates benefits from in metabolic contexts, with acute and chronic exercise inducing its release from , which contributes to exercise-associated . Beyond these, GDF15 concentrations increase with chronological aging and mitochondrial dysfunction, amplifying its role as a of cellular in cardiometabolic pathologies.

In cancer and other conditions

GDF15 exhibits a paradoxical role in cancer , functioning as a tumor suppressor in early stages by inducing in tumor cells and inhibiting progression, while in advanced stages it promotes tumor growth, , and immune evasion. In specific malignancies including pancreatic, colorectal, and cancers, elevated GDF15 expression drives through mechanisms involving anorexia, wasting, and . As a , high circulating GDF15 levels correlate with poor across various solid tumors, with meta-analyses demonstrating associations with reduced overall survival and hazard ratios exceeding 1.5 for mortality in digestive system tumors and . In non-oncological conditions, GDF15 is markedly elevated in mitochondrial myopathies, including , where it serves as a sensitive diagnostic reflecting mitochondrial dysfunction and tissue stress. GDF15 contributes to , a severe disorder characterized by profound and , primarily through maternal hypersensitivity to placentally derived GDF15 acting on receptors. In autoimmune diseases such as , increased serum GDF15 levels are linked to heightened inflammation, disease activity, and joint damage, potentially exerting both pro- and anti-inflammatory effects. Furthermore, in , circulating GDF15 is upregulated in response to renal injury and strongly predicts progression to end-stage renal failure independent of other risk factors. Additionally, elevated GDF15 levels have been observed in as of 2023, associating with symptom severity including persistent fatigue and metabolic dysregulation.

Clinical and therapeutic implications

As a biomarker

GDF15 is commonly measured in or using enzyme-linked immunosorbent assay () kits, such as those developed by R&D Systems, which enable quantification in biological fluids with a typical detection range of 23–1500 pg/mL. In healthy individuals, circulating GDF15 levels increase with age, with medians ranging from approximately 500 pg/mL in younger adults to over 2,000 pg/mL in the elderly, though reference intervals can vary slightly by assay and population demographics. Pathological conditions often result in elevated levels exceeding 1,000 pg/mL, reflecting stress-induced secretion from affected tissues. As a prognostic biomarker, GDF15 provides independent predictive value across several diseases, enhancing risk stratification models. In heart failure and acute coronary syndromes, elevated GDF15 levels (>1,800 pg/mL) serve as an independent predictor of all-cause mortality and , adding incremental prognostic utility to the score when measured on admission. For cancer, high serum GDF15 correlates with poorer overall survival in various malignancies, such as and , and has been explored in combination with (LDH) to improve prognostic accuracy in advanced stages. In mitochondrial diseases, particularly myopathies, GDF15 demonstrates high specificity (>90%) for distinguishing mitochondrial disorders from other myopathies, outperforming biomarkers like FGF-21 in diagnostic panels. Emerging applications of GDF15 include monitoring therapeutic responses and age-related changes. Treatment with metformin, a glucose-lowering agent, elevates circulating GDF15 levels via renal synthesis, allowing its use as a marker to assess metabolic interventions and suppression effects. Similarly, acute exercise induces transient increases in GDF15, which can track physiological adaptations to in healthy and diseased states. In the context of aging, GDF15 serves as a senescence-associated marker, with levels rising progressively and correlating with frailty and , independent of comorbidities.

Therapeutic development

Therapeutic development of GDF15 modulation has focused on both and to address conditions like and metabolic disorders. Antagonists target elevated GDF15 levels that drive suppression and in , while agonists leverage GDF15's role in energy regulation for and cardioprotection. Pfizer's ponsegromab, a that neutralizes GDF15, has shown promise in treating cancer-associated . In a phase 2 randomized, double-blind trial completed in September 2024, patients with advanced cancer, , and elevated serum GDF15 (≥1500 pg/mL) receiving 400 mg ponsegromab every 4 weeks experienced a mean body weight increase of 5.6% at 12 weeks compared to , alongside improvements in , symptoms, , and mass. Lower doses (100 mg and 200 mg) also yielded weight gains of 2.9% and 4.8%, respectively, with no significant differences in adverse events beyond injection-site reactions. An open-label extension as of October 2025 demonstrated sustained body weight improvements and good tolerability over 64 weeks. As of November 2025, phase 3 trials, such as NCT06989437 evaluating ponsegromab combined with in and metastatic pancreatic ductal , remain ongoing to confirm efficacy and safety. Agonists of the GDF15 pathway, including recombinant GDF15, have demonstrated cardioprotective effects in preclinical models of ischemia-reperfusion injury. Administration of exogenous recombinant GDF15 reduced cardiac , , and tissue damage in and models of myocardial ischemia, alleviating diastolic dysfunction independently of . However, therapeutic use is challenged by GDF15's short of approximately 3 hours in humans and animals, due to renal clearance and proteolytic susceptibility, necessitating strategies like Fc-fusion proteins to extend duration of action. Other approaches include GDF15 mimetics targeting the GFRAL receptor for treatment. Amgen's AMG 171, a GDF15 variant fused to an Fc domain for extension, reduced intake and induced in preclinical studies across mice, rats, and obese cynomolgus monkeys, primarily through fat mass reduction without significant muscle loss. However, following termination of the phase 1 trial in 2022 due to insufficient efficacy, further development for has been discontinued. considerations for GDF15 modulation remain preclinical, with potential for sustained expression or knockdown via vectors like CRISPR-Cas9 nanoparticles to enhance or metabolic control, though clinical translation is limited by delivery challenges and off-target effects.

References

  1. [1]
    Overview of growth differentiation factor 15 in metabolic syndrome
    Mar 29, 2023 · GDF 15 circulates in the blood and target heart and other organs to prevent several metabolic diseases such as obesity, liver steatosis or ...
  2. [2]
    Growth Differentiation Factor 15 (GDF15): A Survival Protein with ...
    For example, GDF15 has been reported to inhibit and enhance tumor development and progression as summarized in a recent review (X. Wang, Baek, & Eling, 2013).
  3. [3]
    PLAB, a novel placental bone morphogenetic protein - PubMed
    We have recently isolated a novel member of the BMP family from placenta, termed PLAB. PLAB is expressed highly in placenta, but can be found upon stringent ...
  4. [4]
    MIC-1, a novel macrophage inhibitory cytokine, is a divergent ...
    MIC-1 encodes a protein that bears the structural characteristics of a transforming growth factor β (TGF-β) superfamily cytokine.Missing: et | Show results with:et
  5. [5]
    Cloning and characterization of a novel member of the ... - PubMed
    May 29, 1998 · We cloned a novel member of the BMP family that is expressed at high levels in the placenta and the prostate and that we have designated as prostate-derived ...
  6. [6]
    Cyclooxygenase inhibitors regulate the expression of a TGF-beta ...
    These data demonstrate that NAG-1 is an antitumorigenic and proapoptotic protein, and its regulation by COX inhibitors may provide new clues for explaining ...Missing: et al
  7. [7]
    Characterization of the Rat, Mouse, and Human Genes of growth ...
    Sep 3, 1999 · Characterization of the Rat, Mouse, and Human Genes of growth/differentiation factor-15/macrophage Inhibiting cytokine-1 (GDF-15/MIC-1) ... Gene.
  8. [8]
    9518 - Gene ResultGDF15 growth differentiation factor 15 [ (human)]
    Aug 19, 2025 · Serum growth differentiation factor-15 (GDF-15) is a biomarker of cardiac manifestations in children with COVID-19. FGF21 and GDF15 are elevated ...Missing: chromosome | Show results with:chromosome
  9. [9]
    Gene: GDF15 (ENSG00000130513) - Summary - Homo_sapiens
    Chromosome 19: 18,374,731-18,389,176 forward strand. This gene has 5 transcripts (splice variants), 176 orthologues, 31 paralogues and is associated with 1 ...Missing: positions | Show results with:positions
  10. [10]
    GDF15: A Hormone Conveying Somatic Distress to the Brain
    GDF15 (then termed macrophage inhibitory cytokine-1 [MIC-1]) was discovered by the Breit group in 1997, who used subtraction cloning to identify genes that were ...
  11. [11]
    Growth/differentiation factor 15 - Homo sapiens (Human) | UniProtKB
    Nov 30, 2010 · GDF15 is a hormone produced in response to stresses, triggering an aversive response in the brain, and interacting with GFRAL and RET.
  12. [12]
    Growth Differentiation Factor 15 Maturation Requires Proteolytic ...
    Oct 15, 2018 · In addition, GDF15 contains the canonical RXXR sequence right before the cleavage site, which can be recognized by PCSK1 to -7. These ...
  13. [13]
    Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel ...
    Growth/differentiation factor 15 (GDF-15) is also known as macrophage inhibitory cytokine (MIC)-1, non-steroidal anti-inflammatory drug-inducible gene (NAG)-1, ...
  14. [14]
    GDF15 Gene - GeneCards | GDF15 Protein | GDF15 Antibody
    GDF15 (Growth Differentiation Factor 15) is a Protein Coding gene. Diseases associated with GDF15 include Hyperemesis Gravidarum and Myocardial Infarction.
  15. [15]
    GDF15 protein expression summary - The Human Protein Atlas
    The categories include: cell type enriched, group enriched, cell type enhanced, low cell type specificity and not detected. Immune cell enhanced (neutrophil).
  16. [16]
    Regulation of growth differentiation factor 15 expression by ...
    Feb 12, 2009 · The GDF15 promoter contains 2 functional p53-binding sites, and the p53 transcriptional pathway is known to be up-regulated by hypoxia. However, ...
  17. [17]
    AMPK mediates energetic stress‐induced liver GDF15
    Dec 18, 2020 · GDF15 expression and secretion are regulated by the integrated stress response, a gene expression program that links cellular stress, such as ER ...
  18. [18]
    Role of the Stress- and Inflammation-Induced Cytokine GDF-15 in ...
    GDF-15 is proposed as a biomarker for mortality and disease progression in patients with atherosclerosis and/or cardiovascular disease (CVD).
  19. [19]
    GDF15 as a key disease target and biomarker: linking chronic lung ...
    Apr 24, 2023 · The GDF15 precursor protein undergoes disulphide‐linked dimerisation through a cysteine residue and is then cleaved at the RXXR cleavage ...Gdf15 As A Key Disease... · Gdf15 And Ageing · Role Of Gdf15 In Chronic...<|control11|><|separator|>
  20. [20]
    Macrophages as a Source and Target of GDF-15 - PMC
    Macrophages produce high levels of GDF-15 during oxidative and lysosomal stress, which can lead to fibrogenesis and angiogenesis at the tissue level.
  21. [21]
    Growth Differentiation Factor 15 during pregnancy and postpartum ...
    The study identifies a dramatic plasma GDF15 decline from late pregnancy to early postpartum. •. We found no association between CSF GDF15 in pregnancy and ...Missing: mid- | Show results with:mid-
  22. [22]
    Growth and differentiation factor 15 (GDF15) levels predict adverse ...
    Jan 1, 2023 · Postnatal GDF15 levels decrease after birth, with their lowest level at 36 weeks PMA. This result was contrary to our hypothesis, based on the ...Missing: mid- | Show results with:mid-
  23. [23]
    GDF-15 promotes angiogenesis through modulating p53/HIF-1α ...
    Jul 20, 2011 · Our results suggested that GDF-15 promoted angiogenesis in hypoxic HUVECs possibly through inhibiting p53 signal, which subsequently enhanced and stabolized ...
  24. [24]
    CRP Stimulates GDF15 Expression in Endothelial Cells through p53
    Jun 3, 2018 · Two groups of investigators have demonstrated that adipocytes can synthesize and secrete GDF15 when exposed to oxidative stress. They may ...
  25. [25]
    Regulation of growth differentiation factor 15 expression by ...
    Feb 12, 2009 · The GDF15 promoter contains 2 functional p53-binding sites, and the p53 transcriptional pathway is known to be up-regulated by hypoxia. However, ...
  26. [26]
    The Role of NAG-1/GDF15 in the Inhibition of Intestinal Polyps in ...
    Our laboratory discovered that NSAIDs increase the expression of NSAID-activated gene (NAG-1/GDF15) independent of COX inhibition in human colorectal cancer ...<|control11|><|separator|>
  27. [27]
    Metformin-induced increases in GDF15 are important for ... - PubMed
    Dec 9, 2019 · Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019 Dec;1(12):1202-1208 ...
  28. [28]
    Review Insights Into Mechanisms of GDF15 and Receptor GFRAL
    GDF15 acts as an inflammatory marker, and it plays a role in pathogenesis of tumors, ischemic diseases, metabolic disorders, and neurodegenerative processes.
  29. [29]
    GDF15 is an epithelial-derived biomarker of idiopathic pulmonary ...
    Previous investigations have identified the canonical TGF-β receptors, TGFBR1 and TGFBR2, as potential receptors for GDF15 (14, 32). TGFBR1 and TGFBR2 were ...
  30. [30]
    Role and Mechanism of Growth Differentiation Factor 15 in Chronic ...
    May 9, 2024 · GDF-15 mainly improves the function of kidneys in CKD and plays an important role in the prediction of CKD progression and cardiovascular complications.Missing: sulfation Ser99
  31. [31]
    Role of GDF15 (Growth and Differentiation factor 15) In Pulmonary ...
    GDF-15 promotes angiogenesis through modulating p53/HIF-1α signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep. 2012;39:4017 ...
  32. [32]
    Macrophage inhibitory cytokine 1 mediates a p53-dependent ...
    Protective p53-dependent cell-cycle checkpoints are activated in response to a wide variety of stresses, including not only DNA damage but also arrest of DNA ...
  33. [33]
    CRP Stimulates GDF15 Expression in Endothelial Cells through p53
    Jun 3, 2018 · GDF15 is a direct target gene of p53. It is highly expressed in the placenta during pregnancy but is expressed at low levels in most tissues at ...
  34. [34]
    GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of ...
    GDF15 exerts its effects by reprogramming the metabolic pathways of macrophages to acquire an oxidative phosphorylation–dependent anti-inflammatory functional ...Missing: lung | Show results with:lung
  35. [35]
    Emerging Roles of GDF-15 in Immunoregulation and Pathogenesis
    Furthermore, a compelling study by Chow and colleagues demonstrated that post-translational modification of the GFRAL can also be a mechanism to regulate GDF-15 ...
  36. [36]
    GDF15, an emerging key player in human aging - ScienceDirect
    GDF15 is one of the most up-regulated proteins during aging and a key molecule in the mechanisms of human stress response.
  37. [37]
    Growth differentiation factor 15 promotes blood vessel ... - Nature
    Aug 22, 2017 · These findings confirm that GDF15 promotes angiogenesis through stimulating endothelial cell proliferation, indicating that GDF15 may be a ...
  38. [38]
    GDF15 secreted by senescent endothelial cells improves vascular ...
    May 10, 2019 · Growth Differentiation Factor 15 (GDF15) is a stress response cytokine belonging to the Transforming Growth Factor β superfamily [7,8].
  39. [39]
    Concise Review: Growth Differentiation Factor 15 in Pathology
    GDF15 protects cardiomyocytes against apoptosis and thus protects the heart in ischemia/reperfusion [65].
  40. [40]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC10520366/
  41. [41]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9779231/
  42. [42]
    GDF15 promotes weight loss by enhancing energy expenditure in ...
    Jun 28, 2023 · Treatment of rodents fed a high-fat diet with recombinant growth differentiating factor 15 (GDF15) reduces obesity and improves glycaemic control.
  43. [43]
    The Role of Growth Differentiation Factor 15 in Energy Metabolism
    Jun 29, 2020 · GDF15 acts through a brain-stem-restricted receptor, through which it reduces food intake and lowers body weight.
  44. [44]
    GDF15 linked to maternal risk of nausea and vomiting ... - Nature
    Dec 13, 2023 · The presence of high levels of GDF15 (then called MIC-1) in maternal blood in normal human pregnancy was first reported in 2000 (ref. 10) by ...
  45. [45]
    Fetally-encoded GDF15 & maternal sensitivity determinants of nausea
    Jun 4, 2023 · The placentae of certain higher mammals, including primates, have evolved to produce large amounts of GDF15 from early pregnancy, a phenomenon ...
  46. [46]
    Roles of Growth Differentiation Factor 15 in Atherosclerosis and ...
    75 GDF‐15 deficiency contributes to angiogenesis and improves atherosclerotic plaque stability by impairing macrophage migration and promoting collagen ...
  47. [47]
    Growth differentiation factor-15 as a biomarker of atherosclerotic ...
    Conversely, increased GDF-15 levels were associated with the presence of coronary artery plaques in people without HIV, independently of CV risk factors.
  48. [48]
    GDF-15 as a Biomarker in Cardiovascular Disease - PubMed
    This review aimed to summarize the current evidence on the diagnostic and prognostic value of GDF-15 in different settings in cardiology.
  49. [49]
    GDF15 and Cardiac Cells: Current Concepts and New Insights
    Aug 18, 2021 · It acts as an inflammatory marker and plays a role in the pathogenesis of cardiovascular diseases, metabolic disorders, and neurodegenerative ...
  50. [50]
    Growth differentiation factor 15 predicts cardiovascular events in ...
    Higher levels of GDF-15 consistently provides prognostic information for cardiovascular events and all cause death, independent of clinical risk factors and ...
  51. [51]
    Investigating the Role of GDF-15 in Diabetes and Obesity - NIH
    In animal studies, GDF-15 promotes weight loss by reducing fat mass and adiposity, improving insulin sensitivity and glucose tolerance while maintaining energy ...
  52. [52]
    GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular ...
    Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, ...
  53. [53]
    Growth differentiation factor 15 (GDF15) is associated with non ...
    Feb 22, 2022 · Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity.
  54. [54]
    Exercise training promotes a GDF15-associated reduction in fat ...
    May 1, 2019 · We conclude that the exercise-induced increase in plasma GDF15 and the association with reduced fat mass may indicate a role for GDF15 as a therapeutic target ...
  55. [55]
    Human Aging and Longevity Are Characterized by High Levels of ...
    Apr 23, 2019 · We analyzed FGF21, HN, and GDF15 plasma levels in 693 subjects aged from 21 to 113 years, and the association of these mitokines with parameters ...<|control11|><|separator|>
  56. [56]
    Secreted growth differentiation factor 15 as a potential biomarker for ...
    GDF15 is a useful diagnostic marker for mitochondrial diseases, which are inherited disorders caused by mitochondrial or nuclear genomic mutations that lead to ...
  57. [57]
    GDF15 induced apoptosis and cytotoxicity in A549 cells depends on ...
    Our results indicated that the effect of GDF15 on apoptosis and activation of MAPK in A549 cells depends on TGFBR2 expression.
  58. [58]
    Role of growth differentiation factor 15 in cancer cachexia (Review)
    Sep 13, 2023 · GDF15 plays a number of roles in tumorigenesis. In the initial stages of cancer, it induces tumor cell apoptosis and inhibits cancer progression ...
  59. [59]
    Phase 2 study of the efficacy and safety of ponsegromab in patients ...
    Mar 18, 2024 · Growth differentiation factor 15 (GDF-15) is a cytokine that is implicated in cancer cachexia and may represent both a biomarker of cancer ...<|separator|>
  60. [60]
    Appraising growth differentiation factor 15 as a promising biomarker ...
    Feb 26, 2019 · Moreover, increased GDF-15 expression levels were markedly associated with unfavorable overall survival (OS) in patients with DST (HR = 2.34, 95 ...
  61. [61]
    Growth differentiation factor 15 is a promising diagnostic and ... - NIH
    Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer ... Schober A, Bottner M, Strelau J, et al ...
  62. [62]
    GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is ...
    Feb 11, 2016 · Our results showed that in children with mitochondrial diseases GDF-15 levels were on average increased by 11-fold (mean 4046pg/ml, 1492 SEM) ...
  63. [63]
    GDF15 - Overview: Growth Differentiation Factor 15, Plasma
    A circulating biomarker in myopathy-related mitochondrial disease as well as other conditions. Investigation of patients suspected of having a mitochondrial ...
  64. [64]
    Association of Growth and Differentiation Factor 15 in Rheumatoid ...
    Feb 19, 2022 · Recently, studies have shown that serum levels of GDF-15 were higher in RA patients, correlating with disease activity. However, whether plasma ...
  65. [65]
    Growth differentiation factor 15 as a potential diagnostic biomarker ...
    May 6, 2025 · It has been suggested that GDF-15 may have a bidirectional impact on RA progression, with both proinflammatory and immunosuppressive properties.
  66. [66]
    Growth Differentiation Factor–15 and Risk of CKD Progression - NIH
    Circulating GDF-15 may be a marker for intrarenal GDF15-related signaling pathways associated with CKD and CKD progression. Keywords: chronic kidney disease, ...
  67. [67]
    Human GDF-15 ELISA - Quantikine DGD150 - R&D Systems
    Rating 4.8 (4) The Quantikine Human GDF-15 immunoassay is a 3.5 hour solid phase ELISA designed to measure GDF-15 in cell culture supernates, serum, plasma, and urine.
  68. [68]
    Reference ranges for GDF-15, and risk factors associated with ... - NIH
    Aug 18, 2022 · The limit of detection (LoD) of the GDF-15 assay is set to 400 pg/mL by the manufacturer, and the upper limit of the measuring range was 20,000 ...
  69. [69]
    Serum growth differentiation factor-15 (GDF-15) is a biomarker ... - NIH
    Nov 16, 2023 · The detection range of the kit is 23.438-1500pg/mL. All reagents and samples were brought to room temperature before use.
  70. [70]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8865901/
  71. [71]
    High GDF-15 Serum Levels Independently Correlate with ... - PubMed
    High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma. J ...
  72. [72]
    Accuracy of FGF‐21 and GDF‐15 for the diagnosis of mitochondrial ...
    Jun 25, 2020 · FGF‐21 and GDF‐15 showed acceptable sensitivity and high specificity. Of the biomarkers, GDF‐15 had the highest diagnostic accuracy.
  73. [73]
    Metformin triggers a kidney GDF15-dependent area postrema axis ...
    Apr 14, 2023 · We found that metformin induces GDF15 synthesis in the kidney to increase plasma GDF15 levels and lower food intake and body weight through a ...Missing: aging senescence
  74. [74]
    Growth Differentiation Factor-15 in Immunity and Aging - Frontiers
    Feb 8, 2022 · GDF-15 was independently discovered by multiple laboratories in the late 1990s (Bootcov et al., 1997; Hromas et al., 1997; Lawton et al., 1997; ...
  75. [75]
    NCT06989437 | A Study to Learn About the Medicine Ponsegromab ...
    Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first- ...
  76. [76]
    Exogenous Growth Differentiation Factor 15 (GDF15) exerts direct ...
    These original results suggest that GDF15 exerts direct cardioprotective properties towards ischemia-reperfusion injury. The molecular mechanisms have now ...
  77. [77]
    Long-acting MIC-1/GDF15 molecules to treat obesity - Science
    Oct 18, 2017 · Our work provides evidence that GDF15 Fc fusion proteins could be potential therapeutic agents for the treatment of obesity and related comorbidities.
  78. [78]
    Targeting the GDF15 Signalling for Obesity Treatment
    Dec 19, 2024 · Overexpression of GDF15 has been shown to suppress appetite, resulting in reduced energy intake [29, 33, 39, 80, 81, 82].
  79. [79]
    Targeting GDF15 to enhance immunotherapy efficacy in ...
    Feb 20, 2025 · We demonstrated that the deletion of GDF15 in GBM cells ameliorated the immunosuppressive tumor microenvironment (TME) and enhanced the antitumor efficacy of ...
  80. [80]
    Growth differentiation factor 15 as a potential therapeutic for treating ...
    New and exciting research on GDF15 suggests that it holds promise as a novel obesity treatment as new molecules progress toward clinical development.